PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Fasedienol Nasal Spray Modestly Reduces Public Speaking Distress in Social Anxiety

fasedienolPH94Bpherineintranasalneuroactive nasal spraysocial anxiety disorderpsychiatryphase 3 randomized controlled trialpublic speaking challengeSUDSCGI-IPGI-Cconference abstract Psychiatry / Psychopharmacology

Background Information

Fasedienol nasal spray shows promise for rapid relief in social anxiety.

Fasedienol nasal spray offers a potential new treatment for social anxiety disorder (SAD) with a rapid onset of action. Fasedienol showed a greater reduction in distress scores and improvement in global impressions compared to placebo, with significant results (p=0.015, p=0.033, p=0.003). While promising, this phase 3 data is preliminary. Pharmacists should note its non-systemic action and potential rapid efficacy for SAD. Fasedienol nasal spray could become a novel, rapid-acting treatment for social anxiety disorder.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Liebowitz MR, Salmán E, Hanover R, Reed B, Baker RA, Monti L

Citation: Liebowitz MR, Salmán E, Hanover R, et al. Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder (SAD). CNS spectrums. 2024;29(5):523-524. doi:10.1017/S1092852924002049

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.